3-MeO-PCMo
3-MeO-PCMo is a dissociative anesthetic of the arylcyclohexylamine class, specifically a morpholine analogue of 3-MeO-PCP.1 It functions as an NMDA receptor antagonist and sigma receptor agonist, producing a state of dissociative anesthesia. Notably, it possesses less than one-tenth the potency of its parent compound 3-MeO-PCP.2 It has appeared on the research chemical market as a designer drug1 with very limited data regarding its safety profile or long-term effects.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of MXE and ketamine.
Visual
This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways.
Geometry
The visual geometry of 3-MeO-PCMo can be described as very dark and bland when compared to that of ketamine or DXM. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
Suppressions
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
3-MeO-PCMo is thought to act primarily as an NMDA receptor antagonist, though direct pharmacological characterization remains limited and this attribution is largely inferred from its structural relationship to other arylcyclohexylamines such as PCP and 3-MeO-PCP. In a functional drebrin cluster assay measuring inhibition of NMDA receptor-stimulated activity, 3-MeO-PCMo demonstrated an IC50 of 26.67 μM, considerably less potent than PCP (2.02 μM) or 3-MeO-PCP (1.51 μM).2 Activity at sigma receptors has also been attributed to the substance, though specific binding data is not available.
Pharmacokinetics
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic use can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence.3 Compulsive redosing is reported as a notable cognitive effect.
Physical
LowWhen addiction has developed, cravings and withdrawal effects may occur if usage is suddenly stopped, though the specific nature and severity of physical withdrawal has not been well characterized.
Toxicity
Repeated heavy use, particularly on a daily or weekly basis, can cause bladder and urinary tract problems similar to those seen with ketamine but potentially more severe due to the compound's lower potency requiring larger quantities to achieve equivalent effects; symptoms include urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence.
Psychosis Risk
Mania is listed among potential cognitive effects. As with other dissociatives, there is risk of adverse psychological reactions including anxiety, mania, delusions, and psychosis, with these risks increasing at higher doses.
History & Culture
3-MeO-PCMo is a novel dissociative substance that emerged on the gray market as a designer drug in the mid-2010s. It became available primarily through online research chemical vendors, where it was marketed alongside other novel arylcyclohexylamines.1 As a relatively…
Legality
By Country
References
Source Pages
Citations
- Tristan Colestock, Jason Wallach, Mohammed Mansi, Nasser Filemban, Hamilton Morris, Simon P. Elliott, Folker Westphal, Simon D. Brandt, & Adeboye Adejare. (February 2018). Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Testing and Analysis, 10(2), 272–283. https://doi.org/10.1002/dta.2213123
- Toshinari Mitsuoka, Katsuhiko Hanamura, Noriko Koganezawa, Ruri Kikura-Hanajiri, Yasufumi Sekino, & Tomoyuki Shirao. (September–October 2019). Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay. Journal of Pharmacological and Toxicological Methods, 99, Article 106583. https://doi.org/10.1016/j.vascn.2019.1065831234
- (March 2020). 4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels. Psychopharmacology, 237(3), 757–772. https://doi.org/10.1007/s00213-019-05412-y1
- (April 2011). New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats. Pharmacology, Biochemistry, and Behavior, 98(2), 227–33. https://doi.org/10.1016/j.pbb.2010.12.0191
- (n.d.). Neue-psychoaktive-Stoffe-Gesetz (NpSG) — gesetze-im-internet.de. https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- (n.d.). The Psychoactive Substances Act 2016 (Commencement) Regulations 2016 (SI 2016/553). https://www.legislation.gov.uk/uksi/2016/553/made1
- (n.d.). Psychoactive Substances Act 2016 — CPS Prosecution Guidance. https://www.cps.gov.uk/prosecution-guidance/psychoactive-substances12
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCMo article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.